I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 48 500 VND -0.51% Market Closed
Market Cap: 7.5T VND
Have any thoughts about
Imexpharm Corp?
Write Note

Relative Value

The Relative Value of one IMP stock under the Base Case scenario is 19 165.86 VND. Compared to the current market price of 48 500 VND, Imexpharm Corp is Overvalued by 60%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMP Relative Value
Base Case
19 165.86 VND
Overvaluation 60%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
4
vs Industry
40
Median 3Y
1.3
Median 5Y
1.1
Industry
2.5
Forward
3.2
vs History
4
vs Industry
21
Median 3Y
9.7
Median 5Y
8.9
Industry
21.8
Forward
24
vs History
12
vs Industry
Median 3Y
5.7
Median 5Y
7.8
Industry
16.1
vs History
7
vs Industry
Median 3Y
9.7
Median 5Y
10.7
Industry
23.8
vs History
4
vs Industry
29
Median 3Y
1
Median 5Y
1
Industry
2.1
vs History
4
vs Industry
39
Median 3Y
1.2
Median 5Y
1
Industry
2.7
Forward
3.1
vs History
4
vs Industry
31
Median 3Y
3.1
Median 5Y
2.7
Industry
5.2
vs History
4
vs Industry
29
Median 3Y
5.5
Median 5Y
4.9
Industry
13.5
Forward
14
vs History
4
vs Industry
28
Median 3Y
7
Median 5Y
6
Industry
16.8
Forward
18.2
vs History
12
vs Industry
Median 3Y
4.9
Median 5Y
7.7
Industry
15.2
vs History
17
vs Industry
Median 3Y
7.3
Median 5Y
7.8
Industry
19.3
vs History
4
vs Industry
30
Median 3Y
0.9
Median 5Y
0.9
Industry
1.9

Multiples Across Competitors

IMP Competitors Multiples
Imexpharm Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Imexpharm Corp
VN:IMP
7.5T VND 3.5 30.2 16.6 21.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 90.3 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.9 11.6 15
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.6
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
VN
I
Imexpharm Corp
VN:IMP
Average P/S: 382 942.3
3.5
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
VN
I
Imexpharm Corp
VN:IMP
Average P/E: 32.2
30.2
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBITDA: 415.3
16.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBIT: 1 812.3
21.8
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.6
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top